VKTX
Viking Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
VKTX Profile
Viking Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing therapies for the treatment of metabolic and endocrine disorders
Pharmaceutical
09/24/2012
04/29/2015
NASDAQ Stock Exchange
36
12-31
Common stock
9920 Pacific Heights Blvd, Suite 350, San Diego, California 92121
--
Viking Therapeutics, Inc., was incorporated in Delaware on September 24, 2012. The company is a clinical-stage biopharmaceutical company dedicated to the development of new, first class or best class therapies for metabolic and endocrine disorders. The company has global exclusive rights to licence-based ligand small molecule combinations in five drug candidates in clinical trials or preclinical studies. The company's leading clinical program is VK 0612, an oral drug for the treatment of diabetes that has entered phase 2 b clinical trials as one of the world's largest health challenges for type 2, and it ranks first among the same drugs. The Company's second clinical program, vk 5211, delivers oral drug candidates into Phase 2 clinical trials for the treatment of uncontrolled muscle mass loss cancer cachexia characterized by a complex disease. VK 5211 is a non-steroidal selective androgen receptor modulator, or SARM.